Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.

doi:10.1080/13543776.2024.2358818

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.

Expert opinion on therapeutic patents - 1 Apr 2024

Iliev Petar, Jaworski Carolin, Wängler Carmen, Wängler Björn, Page Brent D G, Schirrmacher Ralf, Bailey Justin J

Abstract excerpt

INTRODUCTION: The Trk family proteins are membrane-bound kinases predominantly expressed in neuronal tissues. Activated by neurotrophins, they regulate critical cellular processes through downstream signaling pathways. Dysregulation of Trk signaling can drive a range of diseases, making the design and study of Trk inhibitors a vital area of research. This review explores recent advances in the development of type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Drug Development
Share to Mutation
Share to Patents as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Receptor, trkA

Share to Signal Transduction

Source

Open in PubMed

Identifiers

PMID: 38785069
DOI: 10.1080/13543776.2024.2358818

Provenance

PubMed metadata and Literature Corpus relationships.